Navigation Links
Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008

Appoints Ronen Tamir as Executive Vice President, Marketing and


REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, December 3 /PRNewswire-FirstCall/ -- Rosetta Genomics (NASDAQ: ROSG) announced today that in preparation for the launch of its first microRNA-based diagnostic products in 2008, it is strengthening its management team. Ronen Tamir has been appointed to the newly created position of Executive Vice President, Marketing and Communication, and will lead the commercialization of the company's first-ever microRNA-based diagnostic products.

"I am very pleased to announce the addition of such an accomplished pharmaceutical executive to our management team," said Amir Avniel, President and CEO of Rosetta Genomics. "Ronen brings with him a successful marketing, investor relations and communications background. His energy and leadership skills will be instrumental to the successful commercialization of our microRNA based products."

Prior to joining Rosetta Genomics, Ronen Tamir was Vice President, Investor Relations for North America at Novartis AG. While Ronen was at Novartis, Novartis significantly increased its North American shareholder base and Ronen's team won numerous awards, including the "Best European IR Team in North America for 2005" by IR magazine, the "Silver Anvil" award by the Public Relations Society of America, and the "Big Apple - Best of the Best" award by the Institution of Public Relations, both for Investor Relations campaign for 2006.

Prior to joining Novartis in 2004, Ronen held several key positions at Serono, including Director of Business Intelligence for North America and Global Product Manager, Neurology, in Geneva, Switzerland, where he oversaw the global launch of Rebif(R), the leading therapy for Multiple Sclerosis. In addition, Ronen was the Regional Product Manager for Neurology and Metabolism for Serono's Intercontinental Business Operations.

Ronen holds a degree in Biology from Bar-Ilan University in Israel and an MBA from Warwick Business School in the UK.

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression levels in certain diseased versus normal tissues. As a result, these differences potentially provide for a novel diagnostic strategy for many diseases. MicroRNAs are thought to play a key role in the differentiation of cells into specific cell types performing various functions in the body.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the development of microRNA-based diagnostics and therapeutics. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and strategic alliances with leading biotechnology companies, Rosetta Genomics is working to develop a full range of diagnostic and therapeutic products based on microRNAs. The company's primary focus is in the development of microRNA-based products to diagnose and treat different forms of cancer and infectious diseases.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease and the potential of microRNAs in the diagnosis and treatment of disease constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Contact: Media

Alan Zachary

T: +1-312-944-6784


Juliane Snowden

T: +1-212-213-0006

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
3. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
4. NeoGenomics, Inc. Schedules its Q3 07 Earnings Conference Call For Wednesday, November 14, 2007 at 11:00 AM
5. NeoGenomics Announces Results for the 3rd Quarter 2007
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. International study strengthens case for daily calcium pill
8. Wachovia Strengthens Its Healthcare Industry Receivables and Cash Management Capabilities
9. Essilor Strengthens its Polarized Lens Distribution Network With the Acquisition of KBco
10. Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy
11. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... The ... perfect dish and pleasing the palates of attendees is of the utmost importance. ... to a seasonal get-together, give these recipes a try this holiday season. , ...
(Date:11/25/2015)... Nairobi (PRWEB) , ... November 26, 2015 , ... ... African Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, ... Nations Office in Nairobi (UNON) for the opening of the 5th African Network ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Smiles ... of TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of ... of the great success Botox® delivers to those suffering with discomfort, soreness, and pain ...
(Date:11/25/2015)... ... , ... “While riding the bus, I saw a passenger in a wheelchair ... to be a convenient and comfortable way to protect them from bad weather, so ... safely travel during cold or inclement weather. In doing so, it ensures that the ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... , Nov. 25, 2015 Endo International plc (NASDAQ: ... De Silva , President and CEO, will discuss corporate updates ... in New York on Wednesday, December ... . Click on Investor Relations, and then the link to ... the presentation,s start time to visit the site and download ...
Breaking Medicine Technology: